Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.37 |
| ▸ | CES1 | P23141 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 3/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | DAO | P14920 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 2/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | SNCA | P37840 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17028528 | 0.91 | HPGD (0.38) | CES2CES1HPGDPOLBDAO | |
| SCHEMBL9085983 | 0.86 | HTT (0.36) | CES2CES1HPGDPOLBDAO | |
| SCHEMBL29134942 | 0.81 | HPGD (0.33) | CES2CES1HPGDPOLBDAO | |
| SCHEMBL17028581 | 0.77 | HPGD (0.32) | CES2CES1HPGDPOLBDAO | |
| SCHEMBL9085747 | 0.73 | SLC6A2 (0.34) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL19507038 | 0.73 | HCAR3 (0.37) | HPGDDAOALDH1A1 | |
| SCHEMBL29268033 | 0.68 | SLC6A2 (0.30) | HPGDPOLBSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL13209013 | 0.67 | SLC6A2 (0.40) | CES2CES1HPGDPOLBDAO | |
| SCHEMBL19475517 | 0.66 | CA2 (0.43) | — | |
| SCHEMBL23878712 | 0.65 | HCAR3 (0.35) | DAOALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3107901-B1 | COMPOUNDS FOR USE AS GPR120 AGONISTS | PIRAMAL ENTPR LTD (IN) | 2020-04-01 | — | — | EP | disclosed |
| US-10227360-B2 | Compounds for use as GPR120 agonists | Piramal Enterprises Limited (IN) | 2019-03-12 | — | — | US | disclosed |
| EP-3107901-A1 | COMPOUNDS FOR USE AS GPR120 AGONISTS | Piramal Enterprises Limited (IN) | 2016-12-28 | — | — | EP | disclosed |
| US-20160347768-A1 | COMPOUNDS FOR USE AS GPR120 AGONISTS | Piramal Enterprises Limited (IN) | 2016-12-01 | — | — | US | disclosed |
| WO-2015125085-A1 | COMPOUNDS FOR USE AS GPR120 AGONISTS | Piramal Enterprises Limited (IN) | 2015-08-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10227360-B2 | Compounds for use as GPR120 agonists | GPR119, GPR55, GPR180 | CES2 3002/4885CES1 1565/4885HPGD 718/4885 |
| US-20160347768-A1 | COMPOUNDS FOR USE AS GPR120 AGONISTS | GPR119, GPR55, GPR180 | CES2 3002/4885CES1 1565/4885HPGD 718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.